Cargando…

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

BACKGROUND: Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warrant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettrich, Thomas J., Berger, Andreas W., Perkhofer, Lukas, Daum, Severin, König, Alexander, Dickhut, Andreas, Wittel, Uwe, Wille, Kai, Geissler, Michael, Algül, Hana, Gallmeier, Eike, Atzpodien, Jens, Kornmann, Marko, Muche, Rainer, Prasnikar, Nicole, Tannapfel, Andrea, Reinacher-Schick, Anke, Uhl, Waldemar, Seufferlein, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311014/ https://www.ncbi.nlm.nih.gov/pubmed/30594153 http://dx.doi.org/10.1186/s12885-018-5183-y

Ejemplares similares

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
por: Perkhofer, L., et al.
Publicado: (2019)

Aios in coronatijd
por: Maria Greijn, Claudia, et al.
Publicado: (2020)

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
por: Ettrich, Thomas J., et al.
Publicado: (2016)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

AIOS proceedings: A response
por: Rajendran, Babu
Publicado: (2009)

19. AIO-Herbstkongress 2022
Publicado: (2023)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer
por: Berger, Andreas W., et al.
Publicado: (2019)

Trends and Challenges in AIoT/IIoT/IoT Implementation
por: Hou, Kun Mean, et al.
Publicado: (2023)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

Causes of mortality in elderly UICC stage III colon cancer (CC) patients––Tumor‐related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry
por: Nöpel‐Dünnebacke, Stefanie, et al.
Publicado: (2022)

AIOS Constitution Reforms - Change is the Secret Sauce for Success
por: Honavar, Santosh G
Publicado: (2021)

AIoT Used for COVID-19 Pandemic Prevention and Control
por: Chen, Shu-Wen, et al.
Publicado: (2021)

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
por: Büttelmann, M., et al.
Publicado: (2023)

An Oxidoreductase AioE is Responsible for Bacterial Arsenite Oxidation and Resistance
por: Wang, Qian, et al.
Publicado: (2017)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
por: Sommerhäuser, G., et al.
Publicado: (2022)

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
por: Hartlapp, I., et al.
Publicado: (2022)

Practical handling of AIO admixtures – Guidelines on Parenteral Nutrition, Chapter 10
por: Mühlebach, S., et al.
Publicado: (2009)

A Partition Based Gradient Compression Algorithm for Distributed Training in AIoT
por: Guo, Bingjun, et al.
Publicado: (2021)

Recent Advancements and Challenges of AIoT Application in Smart Agriculture: A Review
por: Adli, Hasyiya Karimah, et al.
Publicado: (2023)

The Design and Optimization of an Acoustic and Ambient Sensing AIoT Platform for Agricultural Applications
por: Alzuhair, Ahmed, et al.
Publicado: (2023)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
por: Reinacher-Schick, Anke, et al.
Publicado: (2012)

Exploring Computational Thinking Skills Training Through Augmented Reality and AIoT Learning
por: Lin, Yu-Shan, et al.
Publicado: (2021)

AIoT-Enabled Rehabilitation Recognition System—Exemplified by Hybrid Lower-Limb Exercises
por: Lai, Yi-Chun, et al.
Publicado: (2021)

Raspberry Pi-Based Sleep Posture Recognition System Using AIoT Technique
por: Chen, Pei-Jarn, et al.
Publicado: (2022)

Enabling Artificial Intelligence of Things (AIoT) Healthcare Architectures and Listing Security Issues
por: Pise, Anil Audumbar, et al.
Publicado: (2022)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
por: Schimanski, Carl Christoph, et al.
Publicado: (2020)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial
por: Stocker, G., et al.
Publicado: (2023)

Understanding the science of fungal endophthalmitis - AIOS 2021 Sengamedu Srinivas Badrinath Endowment Lecture
por: Das, Taraprasad, et al.
Publicado: (2022)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
por: Li, Bo, et al.
Publicado: (2021)

Artificial Intelligence of Things- (AIoT-) Based Patient Activity Tracking System for Remote Patient Monitoring
por: Malche, Timothy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q3m3887fku0s8l58tqlq7nf7pa